Literature DB >> 10905758

Biochemical and hematological changes in low-level aluminum intoxication.

J González-Revaldería1, M Casares, M de Paula, T Pascual, V Giner, E Miravalles.   

Abstract

The aim of this study was to investigate the biochemical and hematological changes in patients on routine hemodialysis treatment when they were accidentally exposed to moderately high serum aluminum concentrations during a period of time of less than four months. We studied the changes in biochemical and hematological measurements in 33 patients on dialysis in our hospital before and during the exposure to about 0.85 pmol/l of aluminum in dialysis water due to a malfunction of the reverse osmosis system of water purification. Patients showed a decrease in the hemoglobin concentration from 115+/-12.4 g/l to 108+/-12.2 g/l (p=0.026) and in the mean corpuscular hemoglobin concentration from 5.15+/-0.22 to 5.02+/-0.30 mmol/l (p=0.014). Ferritin was decreased from 243+/-192 microg/l to 196+/-163 microg/l (p=0.047) and transferrin saturation from 0.20+/-0.06 to 0.15+/-0.07 (p=0.004). Biochemical measurements related to calcium-phosphate metabolism did not change. Otherwise, all patients showed an increase in serum aluminum from 0.56+/-0.44 to 1.63+/-0.52 micromol/l (p<0.001). No differences were detected in serum aluminum between patients receiving and not receiving oral aluminum salts. Even moderately high aluminum concentrations maintained during a short period of time could produce significant hematological alterations and a depletion of body iron stores before clinical manifestations were evident.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10905758     DOI: 10.1515/CCLM.2000.032

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

1.  Risk factors and consequences of hyperaluminemia in a peritoneal dialysis cohort.

Authors:  Valery Lavergne; Marc Ghannoum; Megan Christie; Van Vo; Paul W Tam; Robert Ting; Tabo Sikaneta
Journal:  Perit Dial Int       Date:  2012-08-01       Impact factor: 1.756

Review 2.  Pharmacology, efficacy and safety of oral phosphate binders.

Authors:  Alastair J Hutchison; Craig P Smith; Paul E C Brenchley
Journal:  Nat Rev Nephrol       Date:  2011-09-06       Impact factor: 28.314

Review 3.  Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.

Authors:  Monique P Curran; Dean M Robinson
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

Review 4.  Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.

Authors:  Mario Cozzolino; Felix Funk; Viatcheslav Rakov; Olivier Phan; Isaac Teitelbaum
Journal:  Curr Drug Metab       Date:  2014       Impact factor: 3.731

5.  Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate.

Authors:  Ismail A Mohammed; Alastair J Hutchison
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.